Ken Shi
Founding Partner @ 5Y Capital
Shanghai, China
Ken Shi is a Series B investor at 5Y Capital in Shanghai focused on Medical and Pharmaceutical. Ken Shi - Founding Partner @ 5Y Capital
- Total investments:
- 20
- Last investment:
- Lead investor:
- 15%
Last updated:
For AI agents: llms.txt
Industries Ken Shi invests in
Stages Ken Shi invests in
Countries Ken Shi invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 4 (20%)
- Pharmaceutical 4 (20%)
- Health Care 3 (15%)
- Biotechnology 3 (15%)
- Artificial Intelligence 3 (15%)
Stage
- Series B 3 (15%)
- Series C 3 (15%)
- Seed 2 (10%)
- Series A 2 (10%)
- Series D 2 (10%)
Country
- China 6 (30%)
- United States 2 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Xbiome
|
Xbiome is the first AI pharmaceutical company in China that specializes in intestinal micro-ecology. It is based on intestinal micro-ecology and relies on AI technology to accurately and personally manage the gut health of 1.3 billion people. The company uses artificial intelligence to analyze patient and donor intestinal (gut) flora to morequickly develop effective pharmaceuticals. | $100M / Series B / Dec 22, 2021 | |
XtalPi
|
XtalPi is a pharmaceutical technology company that is reinventing the industry’s approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform. Through its tightly interwoven quantum mechanics, artificial intelligence, and high-performance cloud computing algorithms, the ID4 platform enablespharmaceutical companies to increase their efficiency, accuracy, and success rate at critical stages of drug R&D. By accelerating the pace of drug discovery and development, XtalPi aims to contribute to a healthier society worldwide.Founded in 2014 by a group of quantum physicists at MIT, XtalPi has since grown into an elite team of researchers with multi-disciplinary expertise in physics, chemistry, pharmaceutical R&D, and algorithm design. XtalPi has received much recognition for its cutting-edge technologies, its innovative solutions, and the breadth of potential applications of its offerings across the pharmaceutical value chain, which has allowed it to gain industry approval and establish strategic partnerships with several top international pharmaceutical companies. | $400M / Series D / Aug 11, 2021 | |
Galixir
|
Galixir is an artificial intelligence technology to promote the research and development of new drugs. Our artificial intelligence drug discovery platform can help drug research and development scientists greatly save time and cost in drug development. At the same time, our platform also provides comprehensive patent protection coverage for thedrugs developed. Relying on cutting-edge artificial intelligence technology, Xingyao combines engineering chemistry, computational chemistry, computational biology, and cloud computing technologies to serve the various processes of drug development. | Series A / Dec 29, 2020 | |
Medbanks
|
Medbanks Network Technology provides data processing services to the healthcare industry. It develops an oncology database of clinical and professional medical services using information collected from hospitals. It was founded in 2014 and is based in Beijing. | $305M / Series E / Dec 21, 2020 | |
|
Xbiome
|
Xbiome is the first AI pharmaceutical company in China that specializes in intestinal micro-ecology. It is based on intestinal micro-ecology and relies on AI technology to accurately and personally manage the gut health of 1.3 billion people. The company uses artificial intelligence to analyze patient and donor intestinal (gut) flora to morequickly develop effective pharmaceuticals. | Nov 27, 2020 | |
|
Xbiome
|
Xbiome is the first AI pharmaceutical company in China that specializes in intestinal micro-ecology. It is based on intestinal micro-ecology and relies on AI technology to accurately and personally manage the gut health of 1.3 billion people. The company uses artificial intelligence to analyze patient and donor intestinal (gut) flora to morequickly develop effective pharmaceuticals. | Series B / Nov 27, 2020 | |
|
XtalPi
|
XtalPi is a pharmaceutical technology company that is reinventing the industry’s approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform. Through its tightly interwoven quantum mechanics, artificial intelligence, and high-performance cloud computing algorithms, the ID4 platform enablespharmaceutical companies to increase their efficiency, accuracy, and success rate at critical stages of drug R&D. By accelerating the pace of drug discovery and development, XtalPi aims to contribute to a healthier society worldwide.Founded in 2014 by a group of quantum physicists at MIT, XtalPi has since grown into an elite team of researchers with multi-disciplinary expertise in physics, chemistry, pharmaceutical R&D, and algorithm design. XtalPi has received much recognition for its cutting-edge technologies, its innovative solutions, and the breadth of potential applications of its offerings across the pharmaceutical value chain, which has allowed it to gain industry approval and establish strategic partnerships with several top international pharmaceutical companies. | $318.8M / Series C / Sep 28, 2020 | |
Taimei Technology
|
Taimei Technology provides a cloud platform for clinical research collaboration. It is dedicated to propelling biopharmaceutical industry development through technology with a focus in the field of clinical research and pharmacovigilance. Taimei Technology cloud platform was designed for clinical research collaboration between sponsors, sites,CROs, patients, regulatory agencies and third-party providers. Its platform offers 6 technology-enabled solutions encompassing data management, project management, electronic regulatory submission, central medical imaging, pharmacovigilance, and drug logistics. Its clients include pharmaceutical enterprises, CRO and research institutes. The company was founded in 2013 and is headquartered in Jiaxing, Zhejiang, China. | $176.2M / Venture - Series Unknown / Sep 28, 2020 | |
|
Galixir
|
Galixir is an artificial intelligence technology to promote the research and development of new drugs. Our artificial intelligence drug discovery platform can help drug research and development scientists greatly save time and cost in drug development. At the same time, our platform also provides comprehensive patent protection coverage for thedrugs developed. Relying on cutting-edge artificial intelligence technology, Xingyao combines engineering chemistry, computational chemistry, computational biology, and cloud computing technologies to serve the various processes of drug development. | $10M / Seed / Aug 17, 2020 | |
|
Xbiome
|
Xbiome is the first AI pharmaceutical company in China that specializes in intestinal micro-ecology. It is based on intestinal micro-ecology and relies on AI technology to accurately and personally manage the gut health of 1.3 billion people. The company uses artificial intelligence to analyze patient and donor intestinal (gut) flora to morequickly develop effective pharmaceuticals. | $14.2M / Series B / Nov 02, 2019 | |
| See all 20 investments → | |||
Co-Investors
About 5Y Capital
5Y Capital is a firm engaged in providing early-stage venture investments. It was formerly known as Morningside Venture Capital. The investment firm manages USD 5bn in dual-currency funds in USD and RMB, backed by world-renowned sovereign wealth funds, family offices, fund of funds, university endowments, pensions, and foundations. It is aninvestment firm of Morningside Group.It was headquartered in Xuhui, Shanghai, China in 2008 by Ken Shi and Richard Liu.
5Y Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Elwin Yuan
Partner
|
|||
Fisher Zhang
Partner
|
|||
|
He Kaiyan
investor
|
|||
|
Ken Shi
Founding Partner
|
|||
Levi Liu
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Ken Shi invest in?
Ken Shi invests primarily in Medical, Pharmaceutical and Health Care startups, most often at Series B and Series C stage. Most of the 20 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Ken Shi?
Public channels for Ken Shi include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Ken Shi last invest?
The most recent investment recorded for Ken Shi closed in Dec 2021. Shizune tracks 20 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
